1. Home
  2. RDNT vs IMVT Comparison

RDNT vs IMVT Comparison

Compare RDNT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RadNet Inc.

RDNT

RadNet Inc.

HOLD

Current Price

$54.83

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$24.96

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDNT
IMVT
Founded
1985
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.0B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
RDNT
IMVT
Price
$54.83
$24.96
Analyst Decision
Strong Buy
Buy
Analyst Count
5
9
Target Price
$86.00
$30.78
AVG Volume (30 Days)
799.9K
1.1M
Earning Date
05-11-2026
02-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,616,630,000.00
N/A
Revenue This Year
$22.78
N/A
Revenue Next Year
$10.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
13.05
N/A
52 Week Low
$45.00
$12.72
52 Week High
$85.84
$29.25

Technical Indicators

Market Signals
Indicator
RDNT
IMVT
Relative Strength Index (RSI) 31.26 46.81
Support Level $54.50 $22.00
Resistance Level $60.05 $24.63
Average True Range (ATR) 2.53 1.25
MACD -0.44 0.08
Stochastic Oscillator 17.38 55.61

Price Performance

Historical Comparison
RDNT
IMVT

About RDNT RadNet Inc.

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: